List view / Grid view
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
16 October 2024 | By
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
Orlando Health Orlando Regional Medical Center is the first hospital in the world to use the blood test.
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring…
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
A new study reveals that pain management could be greatly improved by considering patient sex as fundamental.
Introducing Joanne Kanaan, CEO and co-founder of the French startup Omini. To meet the new challenges of decentralised and personalised healthcare, Omini is developing a multiplex blood testing platform for outpatient management using a new patented biosensor technology. Joanne obtained a PhD in biochemistry and biophysics from the Ecole Normale…
